C-365, as others have said the evidence is still coming out and I don't think there is definitive advice.
I had SRT in 2022, six years after surgery. The surgeon didn't refer me to oncology until PSA had reached 0.2 and said he had had patients where an initial PSA rise had stabilised below 0.2 and caused no further problems.
Like you I tried to find out as much as possible about the treatment at the time. I found a scientific paper which suggested that for slow growing cancer (PSA under 0.45 and doubling time over 8 months) outcomes of SRT were probably no different with or without HT though it would need a bigger study to establish the thresholds definitively. My oncologist concluded it would be better for me to have HT for a period prior to RT but didn't need it afterwards and I followed that advice.
You currently have pretty low PSA (the lab here doesn't even report numbers less than 0.05) and you don't have a long enough sequence for a reliable estimate of doubling time. So it may be you are a good candidate for RT without HT. If your oncologist with the benefit of more recent clinical studies and obviously his/her own experience of patients thinks you may not need HT I would go with that - both treatments have side effects which can be long term and you don't want more of those than necessary.